JNJ vs GSK Comparison: AI Score, Valuation, Performance and Upside
Compare Johnson & Johnson and GSK by vaccine portfolio, oncology pipeline, MedTech vs consumer health strategy, dividend growth, and valuation.
Use this Johnson & Johnson vs GSK comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
JNJ and GSK are closely matched — they split the tracked metrics evenly. JNJ has delivered stronger 1-year price return (+52.22% vs +42.25%), though GSK has the better forward P/E setup (9.84x vs 19.73x for JNJ). Analyst consensus implies meaningfully more upside for GSK (+14.42%) than for JNJ (+6.68%).
| Metric | JNJ | GSK |
|---|---|---|
| AI score | 43.1 | 41.9 |
| AI rank | #874 | #958 |
| Latest close | $255.63 | $50.76 |
| 1M return | +10.52% | +0.04% |
| 6M return | +17.26% | +8.36% |
| 1Y return | +52.22% | +42.25% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | JNJ | GSK |
|---|---|---|
| 1Y ago | $15.12K (+51.2%) started 2025-07-23 | $14.77K (+47.7%) started 2025-07-22 |
| 5Y ago | $18.54K (+85.4%) started 2021-07-26 | $19.98K (+99.8%) started 2021-07-22 |
| 10Y ago | $34.12K (+241.2%) started 2016-07-25 | $33.28K (+232.8%) started 2016-07-22 |
Hypothetical — past performance does not guarantee future results.
| Metric | JNJ | GSK |
|---|---|---|
| Market cap | $609.12B | $101.66B |
| Trailing P/E | 29.32 | 13.54 |
| Forward P/E | 19.73 | 9.84 |
| Price/Sales | 4.18 | 2.32 |
| EV/Revenue | 6.56 | 3.58 |
| Analyst target | $269.95 | $58.08 |
| Target upside | +6.68% | +14.42% |
| Metric | JNJ | GSK |
|---|---|---|
| Revenue growth | 6.60% | 1.50% |
| Earnings growth | -1.00% | 8.40% |
| EPS growth | -1.00% | +8.40% |
| FCF margin | +12.78% | +9.21% |
| Operating margin | 28.61% | N/A |
| Profit margin | 21.48% | 17.78% |
| ROIC proxy | 26.42% | 40.91% |
| Return on equity | 26.42% | 40.91% |
| Dividend yield | 2.12% | 3.54% |
| Beta | 0.23 | 0.30 |
| Debt/equity | 67.73 | 109.70 |
| Current ratio | 1.02 | 0.79 |
| Quick ratio | 0.69 | 0.51 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | JNJ | GSK |
|---|---|---|---|
| 1Y | Growth | +51.17% | +42.25% |
| CAGR | +51.32% | +42.29% | |
| Sharpe ratio | 2.14 | 1.28 | |
| Max drawdown | 10.96% | 18.53% | |
| Max daily drop | 2.69% | 5.64% | |
| Max wkly drop | 6.22% | 7.81% | |
| 5Y | Growth | +65.60% | +58.99% |
| CAGR | +10.63% | +9.72% | |
| Sharpe ratio | 0.41 | 0.32 | |
| Max drawdown | 18.41% | 37.63% | |
| Max daily drop | 7.59% | 8.69% | |
| Max wkly drop | 9.18% | 13.87% | |
| 10Y | Growth | +160.32% | +84.35% |
| CAGR | +10.05% | +6.31% | |
| Sharpe ratio | 0.37 | 0.18 | |
| Max drawdown | 27.37% | 37.63% | |
| Max daily drop | 10.04% | 11.04% | |
| Max wkly drop | 13.25% | 17.31% |
| Category | JNJ | GSK |
|---|---|---|
| Company | JNJ | GSK |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.